HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6…
Airwheel at Canton Fair 2026: Discover AI-Powered Luxury Rideable Electric 20inch Cabin Boarding Travel Smart Carry on Hand Suitcase
Avantor Expands RIM Single-Use Portfolio Across APAC
HKTDC backs new blueprint for Hong Kong’s next chapter
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops
Critical Minerals Minister Officially Opens GMG’s Gen 2.0 Graphene Manufacturing Plant